We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Argenta Discovery Ltd. has announced that it has extended its integrated contract drug discovery agreement with Genentech, Inc. for a further two-year period.

The first collaboration project under the agreement was announced in December 2005, and a second project was entered into in March 2007. The two programmes utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

Commenting on the extended agreements, Dr. Christopher Ashton, Argenta’s Chief Executive Officer, said, “We are delighted that Genentech has chosen to extend the collaboration for another two years. The two projects have made excellent progress and a good working relationship has been established between both teams of scientists over the past two years.

We believe this extension illustrates Argenta’s key strengths and continued commitment to deliver high quality, time- and cost-effective integrated drug discovery services and expertise. We very much look forward to continuing and growing our successful collaboration with Genentech.”

Financial terms of the deal, which incorporates a number of funded FTEs at Argenta for the next two years, were not disclosed. The agreement provides further options to expand the relationship.